Sec Form 4 Filing - Griffin William L. Jr @ Wright Medical Group N.V. - 2015-10-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Griffin William L. Jr 2. Issuer Name and Ticker or Trading Symbol Wright Medical Group N.V. [ WMGI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP GM BioMimetic Therapeutics (Last) (First) (Middle) 1023 CHERRY ROAD 3. Date of Earliest Transaction (MM/DD/YY) 10/01/2015 (Street) MEMPHIS, TN38117 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares, par value EUR 0.03 per share 10/01/2015 A 71,126 A 71,126 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 28.99 10/01/2015 A 103,090 10/01/2015 07/22/2018 Ordinary Shares 103,090 ( 2 ) 103,090 D Stock Option (Right to Buy) $ 15.01 10/01/2015 A 12,175 10/01/2015 05/13/2019 Ordinary Shares 12,175 ( 3 ) 12,175 D Stock Option (Right to Buy) $ 17.82 10/01/2015 A 10,191 10/01/2015 05/13/2020 Ordinary Shares 10,191 ( 4 ) 10,191 D Stock Option (Right to Buy) $ 15.04 10/01/2015 A 13,252 10/01/2015 05/11/2021 Ordinary Shares 13,252 ( 5 ) 13,252 D Stock Option (Right to Buy) $ 17.7 10/01/2015 A 2,036 10/01/2015 04/16/2022 Ordinary Shares 2,036 ( 6 ) 2,036 D Stock Option (Right to Buy) $ 20.75 10/01/2015 A 20,687 10/01/2015 05/09/2022 Ordinary Shares 20,687 ( 7 ) 20,687 D Stock Option (Right to Buy) $ 23.93 10/01/2015 A 20,564 10/01/2015 05/14/2023 Ordinary Shares 20,564 ( 8 ) 20,564 D Stock Option (Right to Buy) $ 29.06 10/01/2015 A 18,137 10/01/2015 05/13/2024 Ordinary Shares 18,137 ( 9 ) 18,137 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Griffin William L. Jr 1023 CHERRY ROAD MEMPHIS, TN38117 SVP GM BioMimetic Therapeutics Signatures /s/ Marija S. Nelson, Attorney-in-fact 10/05/2015 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Received in exchange for 68,995 common shares of Wright Medical Group, Inc. ("Wright") pursuant to the Agreement and Plan of Merger by and among the issuer, Tornier N.V. ("TRNX"), Trooper Holdings Inc., and Trooper Merger Sub Inc., which became effective on October 1, 2015, (the "Merger"). On the date prior to the effective time of the Merger, the closing price of Wright's common shares was $21.02 per share and the closing price of TRNX's ordinary shares was $20.39 per share. ( 2 )Received in the merger in exchange for an employee stock option to acquire 100,000 Wright shares for $29.88 per share. ( 3 )Received in the merger in exchange for an employee stock option to acquire 11,811 Wright shares for $15.47 per share. ( 4 )Received in the merger in exchange for an employee stock option to acquire 9,886 Wright shares for $18.37 per share. ( 5 )Received in the merger in exchange for an employee stock option to acquire 12,855 Wright shares for $15.50 per share. ( 6 )Received in the merger in exchange for an employee stock option to acquire 1,975 Wright shares for $18.24 per share. ( 7 )Received in the merger in exchange for an employee stock option to acquire 20,067 Wright shares for $21.39 per share. ( 8 )Received in the merger in exchange for an employee stock option to acquire 19,948 Wright shares for $24.66 per share. ( 9 )Received in the merger in exchange for an employee stock option to acquire 17,594 Wright shares for $29.95 per share.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.